ARGS Argos Therapeutics, Inc.

0.48
0  -20%
Previous Close 0.60
Open 0.60
Price To book 4.00
Market Cap 19.77M
Shares 41,355,000
Volume 2,459,724
Short Ratio 2.50
Av. Daily Volume 1,189,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial recommended be discontinued for futility - February 22, 2016. Noted April 18, 2017 that it intends to continue the trial based on post-hoc subgroup analysis.
AGS-003 ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 2 initiated 1Q 2016. Ongoing as of November 2016.
AGS-003
Non-Small Cell Lung Cancer
Phase 2 second stage commenced dosing July 2016. Ongoing as of March 2017.
AGS-004
HIV
Phase 2 trial initial data due 1H 2017.
AGS-003
Early stage renal cell carcinoma (RCC) - cancer

Latest News

  1. The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of Argos Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 15, 2017
  2. DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm
  3. Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
  4. Chief medical officer departs troubled Argos
  5. The Klein Law Firm Announces a Class Action Has Been Filed on Behalf of Argos Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 15, 2017
  6. ETFs with exposure to Argos Therapeutics, Inc. : April 7, 2017
  7. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  8. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc. - Sets Lead Plaintiff Deadline of May 15, 2017 - ARGS
  9. 3 of the Best & Worst Performing Drug Stocks of Q1
  10. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. (ARGS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  11. ARGS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017
  12. INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc.
  13. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  14. ETFs with exposure to Argos Therapeutics, Inc. : March 27, 2017
  15. Lifshitz & Miller LLP Announces Investigation of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. and VAALCO Energy, Inc.
  16. Argos receives termination notice for Centennial Campus lease
  17. IMPORTANT ARGOS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Argos Therapeutics, Inc. in the Middle District of North Carolina
  18. Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  19. ARGS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017
  20. SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. (ARGS) To Contact Brower Piven Before The Lead Plaintiff Deadline